Login to Your Account

Bench Press

Monday, March 28, 2011
Scientists from Massachusetts General Hospital have looked at how non-small-cell lung cancers (NSCLC) that start out sensitive to EGFR kinase inhibitors such as erlotinib (Tarceva) develop resistance.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription